Karyopharm Therapeutics (KPTI) Debt Ratio (2024 - 2026)

Karyopharm Therapeutics (KPTI) has reported Debt Ratio for 3 consecutive years, with 1.13 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Debt Ratio rose 23.26% year-over-year to 1.13; the trailing twelve-month figure through Jun 2026 stood at 1.13 (up 23.26% YoY), and the FY2025 full-year result was 1.07, up 85.64% from the prior year.
• Debt Ratio grew to 1.13 in Q2 2026 per KPTI's latest filing, from 1.07 in the prior quarter.
• Across five years, Debt Ratio topped out at 1.13 in Q2 2026 and bottomed at 0.44 in Q2 2024.
• Historically, Debt Ratio has averaged 0.8 across 3 years, with a median of 0.83 in 2025.
• The sharpest annual moves came in 2025 and 2026: Debt Ratio jumped 109.04% in 2025, then advanced 23.26% in 2026.
• Over 3 years, Debt Ratio stood at 0.58 in 2024, then soared by 85.64% to 1.07 in 2025, then gained by 5.42% to 1.13 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 1.13, 1.07, and 1.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.